Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Four ...
DexCom (NASDAQ:DXCM – Get Free Report) had its price objective increased by research analysts at Barclays from $90.00 to $93.00 in a report issued on Monday,Benzinga reports. The brokerage presently ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Shares in Dexcom plunged in extended trading Thursday after the medical devices company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback